Peer Comparison Analysis: Building a Framework Using Prospectus Data Points

The 2025-2026 listing pipeline in Hong Kong is undergoing a structural recalibration. After a period of subdued primary market activity — with HKEX recording only 68 IPOs raising a total of HKD 87.5 billion in 2024, down from HKD 104.6 billion in 2023 — the exchange is now seeing a resurgence in filing volumes, particularly from mainland Chinese companies in the new economy and advanced manufacturing sectors. This recovery is occurring against the backdrop of the SFC and HKEX’s joint consultation on Listing Regime enhancements for specialist technology companies (Chapter 18C of the Main Board Listing Rules), which took effect on 31 March 2023, and the subsequent first wave of 18C listings in late 2024 and early 2025. For investment banks structuring IPOs, research analysts initiating coverage, and corporate IPO project teams, the ability to rapidly and accurately benchmark a prospective issuer against its listed peers has become a critical competitive advantage. Prospectus documents — from the HKEX’s Main Board and GEM filings, to SEC S-1 registrations and PRC prospectuses — contain a wealth of standardised, audited data points that, when systematically extracted, form the backbone of a defensible peer comparison framework. This article outlines a rigorous methodology for constructing such a framework, focusing on the specific data fields, regulatory touchpoints, and analytical adjustments required to produce actionable intelligence for IPO valuation and market positioning.

The Core Data Points: From Prospectus to Peer Matrix

The foundation of any peer comparison analysis is a standardised data extraction template. A prospectus, whether for a Main Board listing under Chapter 9 of the HKEX Listing Rules or a GEM listing under Chapter 7 of the GEM Listing Rules, contains a prescribed set of financial and operational disclosures. The key is to identify the data points that are both comparable across issuers and material to the valuation of the sector.

Revenue Recognition and Segment Reporting

The single most critical data point for peer comparison is the revenue breakdown by business segment, as disclosed under HKAS 1 (Presentation of Financial Statements) and HKFRS 15 (Revenue from Contracts with Customers). For a company in the advanced manufacturing sector, for example, a prospectus will typically disaggregate revenue into product categories, end-market verticals (e.g., automotive, aerospace, medical devices), and geographic regions. The analyst must normalise this data. A peer issuer might report “Automotive Revenue” while another reports “New Energy Vehicle (NEV) Components Revenue.” The framework must define a standard taxonomy — for instance, “Automotive (ICE + NEV)” vs. “Automotive (NEV-only)” — and then reclassify each peer’s reported segment data accordingly. The HKEX’s 2024 thematic review of financial statement disclosures (published in June 2024) found that 34% of listed issuers had at least one material deficiency in segment reporting, underscoring the need for manual adjustment and cross-referencing with the business description in the prospectus’s “Industry Overview” section.

Gross Margin and Cost Structure

Gross margin is a primary differentiator of business model quality. The prospectus’s “Summary of Financial Information” (typically Section 5 of a Main Board prospectus) provides a five-year historical track record. The analyst must extract gross profit and revenue for each year, calculate the margin, and then compare it against the peer set. However, the real insight lies in the cost structure. A company with a 45% gross margin but a 30% raw material cost ratio is fundamentally different from a peer with a 45% gross margin but a 15% raw material cost and a 15% depreciation cost. The “Notes to the Financial Statements” section (typically Note 4 or 5, “Revenue and Segment Information”) and the “Management Discussion and Analysis” (MD&A) section provide this granularity. For a 2025 IPO candidate in the semiconductor equipment space, the prospectus might disclose that cost of goods sold includes “raw materials (65%), direct labour (12%), and manufacturing overheads (23%).” A peer comparison framework must capture these ratios and adjust for differences in asset intensity (e.g., a fabless vs. an IDM business model).

Customer and Supplier Concentration

Concentration risk is a key due diligence point for sponsors under the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (paragraph 17.6(d)(ii)), which requires sponsors to identify and assess any material risks, including dependence on a limited number of customers or suppliers. The prospectus will disclose the “Top 5 Customers” and “Top 5 Suppliers” as a percentage of total revenue and total purchases, respectively. A peer comparison framework must track these percentages. A company with its top customer accounting for 40% of revenue is exposed to a different risk profile than a peer with a 15% top customer concentration. The framework should also capture the nature of the relationship: is the top customer a related party (e.g., a parent company or a joint venture partner)? This is disclosed in the “Related Party Transactions” section (Note 10 or 11). For a 2025 GEM listing, the threshold for “material related party transaction” is defined under Chapter 20 of the GEM Listing Rules, and the prospectus must disclose the exact transaction amounts.

Building the Financial Model: Adjustments and Normalisation

Raw prospectus data is rarely directly comparable. A robust peer comparison framework requires a series of standardising adjustments to account for differences in accounting policies, capital structure, and operating models.

Accounting Policy Alignment: Revenue Recognition and Leases

The first adjustment relates to revenue recognition. Under HKFRS 15, companies may recognise revenue at a point in time (e.g., upon delivery of a product) or over time (e.g., for a long-term service contract). A peer set might include both models. For a company in the engineering procurement and construction (EPC) sector, a peer using the “percentage of completion” method will report higher revenue in the early years of a project compared to a peer using the “completed contract” method. The framework must adjust the peer’s revenue to a “cash basis” or “contractual milestone basis” by referencing the contract asset and contract liability balances disclosed in the notes to the financial statements (HKFRS 15, paragraphs 116-122). Similarly, the adoption of HKFRS 16 (Leases) on 1 January 2019 required lessees to recognise a right-of-use asset and a lease liability. A peer comparison of EBITDA must back out the depreciation of the right-of-use asset and the interest on the lease liability to arrive at a “pre-IFRS 16” EBITDA, or, alternatively, use “Adjusted EBITDA” as defined in the prospectus, which often excludes these items. The 2024 HKEX review of financial statements found that 12% of issuers had errors in their HKFRS 16 disclosures.

Capital Structure Adjustments: Debt, Equity, and Minority Interests

Enterprise value (EV) is the most common valuation multiple base, but the prospectus data must be carefully normalised. EV = Market Capitalisation + Total Debt + Preferred Stock + Non-Controlling Interests (NCI) – Cash and Cash Equivalents. The prospectus’s “Capitalisation Table” (typically Section 6 of the “Financial Information” section) provides the exact debt composition: bank loans, bonds, convertible notes, and lease liabilities. The “Notes to the Financial Statements” (Note 7 or 8, “Borrowings”) will break down debt by currency, maturity, and interest rate. For a company with a significant NCI (e.g., a subsidiary that is not 100% owned), the framework must include the NCI in the EV calculation. The “Statement of Changes in Equity” (Note 15) provides the NCI balance. A failure to include NCI can lead to a material undervaluation of the enterprise, particularly for companies with joint ventures or partially owned subsidiaries.

Operating Metric Normalisation: Unit Economics

For many new economy companies, traditional financial metrics (P/E, EV/EBITDA) are insufficient. The prospectus must be mined for operating metrics that reflect the underlying business model. For a platform company, this includes Gross Merchandise Value (GMV), Take Rate (revenue as a % of GMV), and Average Revenue Per User (ARPU). For a SaaS company, it is Annual Recurring Revenue (ARR), Net Revenue Retention (NRR), and Customer Acquisition Cost (CAC) payback period. The prospectus’s “Business” section (typically Section 4) and the “MD&A” section will contain these metrics, often with a definition and a reconciliation to the financial statements. The framework must standardise these definitions. One peer might define ARPU as “revenue / average monthly active users,” while another uses “revenue / average quarterly active users.” The analyst must adjust the denominator to a common time period. The SFC’s 2023 guidance on “Disclosure of Non-GAAP Financial Measures” (circular dated 15 December 2023) reminds issuers that these metrics must be clearly defined, consistently calculated, and reconciled to the most directly comparable GAAP measure. A peer comparison framework that uses non-GAAP metrics must verify that each peer’s definition aligns with the SFC’s guidance.

Sector-Specific Considerations and Regulatory Frameworks

The peer comparison framework is not a one-size-fits-all template. Each sector has specific regulatory and operational nuances that must be reflected in the data points selected and the analytical adjustments applied.

Biotech and Healthcare (Chapter 18A)

For biotech companies listed under Chapter 18A of the Main Board Listing Rules, the core value driver is not revenue but the clinical pipeline. The prospectus will disclose the “Core Product” and its development stage (Phase I, II, III, NDA/BLA submission). The peer comparison framework must map each peer’s pipeline by therapeutic area (e.g., oncology, neurology, rare diseases) and by mechanism of action (e.g., small molecule, monoclonal antibody, cell therapy). The key operating metrics are: number of clinical trials, patient enrolment targets, estimated trial completion dates, and probability of success (PoS). The prospectus’s “Industry Overview” section, often prepared by a third-party consultant (e.g., Frost & Sullivan), will provide market sizing data and PoS benchmarks. The framework must also account for the regulatory pathway: is the drug being developed under the PRC’s NMPA, the US FDA, or the EU EMA? The HKEX’s 2024 update to Chapter 18A (effective 1 January 2025) introduced new disclosure requirements on the “expected timeline to commercialisation” and “pricing and reimbursement strategy” for core products, which must be incorporated into the peer comparison matrix.

SPAC and De-SPAC Transactions

The peer comparison for a Special Purpose Acquisition Company (SPAC) listing, governed by Chapter 18B of the Main Board Listing Rules, requires a different analytical lens. The SPAC itself has no operating business; the comparison is of the De-SPAC target. The prospectus for the De-SPAC transaction (the “Business Combination Announcement” and the “Shareholder Circular”) will contain the same financial and operating data as a traditional IPO prospectus, but with additional disclosures on the SPAC’s sponsor economics, the redemption rate, and the earn-out structure. The peer comparison framework must isolate the target’s standalone financials (pre-SPAC) and compare them against a set of traditional IPO peers. The key adjustment is to the capital structure: the De-SPAC target’s equity will be diluted by the sponsor’s promote shares and any PIPE (Private Investment in Public Equity) investors. The framework must calculate a “fully diluted” market capitalisation, including all outstanding SPAC warrants and the earn-out shares. The SFC’s 2024 circular on SPACs (dated 22 March 2024) emphasised the need for sponsors to disclose the “fair value of the sponsor’s promote” and the “potential dilution to public shareholders,” which are data points to be extracted and compared across De-SPAC transactions.

Real Estate Investment Trusts (REITs)

For REITs listed under Chapter 14 of the Main Board Listing Rules, the core metric is not net profit but Distributable Income and Net Asset Value (NAV). The prospectus will disclose the “Pro Forma Distributable Income” for the most recent financial year, along with the “Property Valuation Report” prepared by an independent valuer. The peer comparison framework must extract the following for each peer: Gross Rental Income, Net Property Income (NPI), NPI Margin, Occupancy Rate, Weighted Average Lease Expiry (WALE), and Loan-to-Value (LTV) Ratio. The LTV ratio is a critical regulatory metric under the HKMA’s Supervisory Policy Manual (SPM) module CR-G-2, which sets a maximum LTV of 50% for REITs. The framework must verify that each peer’s LTV is calculated on the same basis — gross debt vs. net debt, and whether the property valuation is based on an “existing use” or “market value” basis. The 2024 HKEX review of REIT disclosures found that 8% of REITs had inconsistencies in their LTV calculations.

Actionable Takeaways for the IPO Project Team

1. Standardise the data extraction template before the first prospectus review. The template should include at least 50 data points covering revenue segmentation, cost structure, customer/supplier concentration, capital structure, and sector-specific operating metrics, with a clear definition for each field to ensure cross-peer comparability.

2. Adjust for accounting policy differences as a mandatory step, not an optional refinement. Backing out the impact of HKFRS 16 on EBITDA and normalising revenue recognition methods under HKFRS 15 can change a peer’s valuation multiple by 10-20%, and the SFC’s 2023 guidance on non-GAAP measures requires these adjustments to be clearly documented.

3. Incorporate the regulatory framework of the listing venue into the peer set. A Chapter 18A biotech issuer should not be benchmarked against a fully commercialised pharmaceutical company; the peer set must be restricted to companies at a comparable clinical stage, using the same exchange’s disclosure requirements as the baseline.

4. Validate every non-GAAP operating metric against the prospectus’s reconciliation to the financial statements. The SFC’s 2023 circular on non-GAAP measures requires issuers to reconcile these metrics to the most directly comparable GAAP measure, and the peer comparison framework must verify that each peer’s definition is consistent.

5. Build a dynamic model that updates as new prospectus filings are published. The HKEX’s IPO pipeline for 2025 includes over 80 active filings as of Q1 2025, and the peer comparison framework must be refreshed with each new prospectus to maintain its relevance for valuation and market positioning decisions.